Pembrolizumab induced durable antitumor activity among patients with advanced, metastatic esophageal cancer whose disease progressed after two or more lines of treatment, according to results of the open-label, phase 2 KEYNOTE-180 study published in JAMA Oncology.
https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/in-the-journals/%7B5765ddbf-76e1-4460-9e4c-d00d12132781%7D/pembrolizumab-confers-durable-benefit-in-advanced-esophageal-cancer
Pembrolizumab confers durable benefits in advanced esophageal cancer